Document is current
Any future updates will be listed below
-
Authors
Iqbal, Madiha https://orcid.org/0000-0001-6752-5440
Jagadeesh, Deepa
Chavez, Julio
Khurana, Arushi
Rosenthal, Allison
Craver, Emily https://orcid.org/0000-0003-0334-9606
Epperla, Narendranath https://orcid.org/0000-0002-8216-3457
Li, Zhuo
Isufi, Iris
Awan, Farrukh T.
Dholaria, Bhagirathbhai R. https://orcid.org/0000-0003-2371-3655
Maakaron, Joseph E. https://orcid.org/0000-0002-1732-6694
Sandoval-Sus, Jose D.
Mishra, Rahul
Saha, Aditi https://orcid.org/0000-0003-3421-3971
Annunzio, Kaitlin
Bhaskar, Shakthi T.
Sumransub, Nuttavut https://orcid.org/0000-0001-7456-0623
Fijalka, Andrew
Ivanov, Stanislav A.
Lin, Yi https://orcid.org/0000-0002-1556-6416
Kharfan-Dabaja, Mohamed A. https://orcid.org/0000-0001-7394-5185
- License Information
-
More Information
Article History
Received: 9 August 2023
Revised: 18 October 2023
Accepted: 3 November 2023
First Online: 16 November 2023
Competing interests
: AR: educational session honoraria for Curio Science and MJH Life Sciences; NE: Research funding: Beigene, Speakers Bureau for Incyte and Beigene, Honoraria/consulting/ad boards for Merck, ADC Therapeutics, Lilly, Novartis; FTA: consultancy to Genentech, Astrazeneca, Abbvie, Janssen, Pharmacyclics, Gilead sciences, Kite pharma, Celgene, Karyopharm, MEI Pharma, Verastem, Incyte, Beigene, Johnson and Johnson, Dava Oncology, BMS, Merck, Cardinal Health, ADCT therapeutics, Epizyme, Caribou Biosciences, Cellecter Bisosciences, Loxo Oncology, and received research funding from Pharmacyclics; BD: Institutional research funding: Janssen, Angiocrine, Pfizer, Poseida, MEI, Orcabio, Wugen, Allovir; Consultancy/Advisor: Jazz, Gamida Cell, MJH BioScience, Arivan Research, BEAM therapeutics, Janssen, Atheneum; JEM: My institution receives research funding on my behalf from Gilead, Atara, CRISPR, Precision Biosciences, Scripps, FATE Therapeutics; JDSS: Speaker’s bureau: Seagen; Consultant: Abbvie, BeiGene, Genmab, Janssen, Genentech, ADC therapeutics, MassiveBio; educational programs: Curio; MAK-D: research/clinical trial with Novartis and Bristol Myers Squibb. The remaining authors have no relevant conflicts of interest to disclose.
